Figure 2 | Laboratory Investigation

Figure 2

From: Sphinganine-1-phosphate protects kidney and liver after hepatic ischemia and reperfusion in mice through S1P1 receptor activation

Figure 2

Selective S1P1 receptor antagonist W146 prevents hepatic (a, ALT) and renal (b, creatinine) protection by sphinganine-1-phosphate and S1P in C57BL/6 mice subjected to 60 min liver ischemia and 24 h reperfusion. Mice were pretreated with vehicle (0.4% fatty acid free BSA, Veh, N=6), W146 (a selective S1P1 receptor antagonist, 0.05 mg/kg i.p., N=6), JTE-013 (JTE, a selective S1P2 receptor antagonist, 0.1 mg/kg i.p., N=6) or BML-241 (BML, a selective S1P3 receptor antagonist, 0.1 mg/kg i.p., N=6) 20 min before sphinganine-1-phosphate or S1P treatment. Sphinganine-1-phosphate or S1P was administered 0.1 mg/kg i.v. immediately before reperfusion and 0.2 mg/kg s.c. 2 h after reperfusion. Data are presented as means±s.e.m. *P<0.05 vs vehicle-treated hepatic IR group. #P<0.05 vs vehicle-treated sphinganine-1-phosphate hepatic IR group. $P<0.05 vs vehicle-treated S1P hepatic IR group.

Back to article page